|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary** **Table 3.** Summary of TEAEs of abnormal peripheral sensationthrough week 80 (treatment + follow-up periods) | | | |
| **N (%) of patients** | **Tanezumab**  **5 mg**  **(n = 92)** | **Tanezumab**  **10 mg**  **(n = 93)** | **Celecoxib**  **200 mg**  **(n = 92)** |
| Any TEAE | 10 (10.9) | 5 (5.4) | 7 (7.6) |
| Specific TEAE\*  Hypoesthesia  Carpal tunnel syndrome  Dysesthesia  Neuralgia  Sciatica  Paresthesia | 6 (6.5)  1 (1.1)  1 (1.1)  1 (1.1)  1 (1.1)  0 | 3 (3.2)  2 (2.2)  0  0  0  1 (1.1) | 5 (5.4)  0  0  0  2 (2.2)  0 |
| Terms included in this analysis were: allodynia; axonal neuropathy; burning sensation; carpal tunnel syndrome; decreased vibratory sense; demyelinating polyneuropathy; dysesthesia; formication; hyperesthesia; hyperpathia; hypoesthesia; hypoesthesia oral; intercostal neuralgia; neuralgia; neuritis; neuropathy peripheral; paresthesia; paresthesia oral; peripheral sensorimotor neuropathy; peripheral sensory neuropathy; polyneuropathy; polyneuropathy chronic; sciatica; sensory disturbance; sensory loss; tarsal tunnel syndrome; thermohypoesthesia.\*Patients could have more than one specific TEAE of abnormal peripheral sensation. TEAE = treatment-emergent adverse event. | | | |